DE69916811D1 - Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden - Google Patents

Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden

Info

Publication number
DE69916811D1
DE69916811D1 DE69916811T DE69916811T DE69916811D1 DE 69916811 D1 DE69916811 D1 DE 69916811D1 DE 69916811 T DE69916811 T DE 69916811T DE 69916811 T DE69916811 T DE 69916811T DE 69916811 D1 DE69916811 D1 DE 69916811D1
Authority
DE
Germany
Prior art keywords
glp
micella
aggregates
derivatives
content over
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69916811T
Other languages
English (en)
Other versions
DE69916811T2 (de
Inventor
Bjerre Knudsen
Olaf Huusfeldt
Franklin Nielsen
C Kaarsholm
Birk Olsen
Erik Bjorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE69916811D1 publication Critical patent/DE69916811D1/de
Application granted granted Critical
Publication of DE69916811T2 publication Critical patent/DE69916811T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69916811T 1998-02-27 1999-02-25 Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden Expired - Lifetime DE69916811T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK26898 1998-02-27
DK26898 1998-02-27
DK27298 1998-02-27
DK27298 1998-02-27
PCT/DK1999/000084 WO1999043341A1 (en) 1998-02-27 1999-02-25 Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Publications (2)

Publication Number Publication Date
DE69916811D1 true DE69916811D1 (de) 2004-06-03
DE69916811T2 DE69916811T2 (de) 2005-04-14

Family

ID=26063652

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69916811T Expired - Lifetime DE69916811T2 (de) 1998-02-27 1999-02-25 Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden

Country Status (6)

Country Link
EP (1) EP1061946B1 (de)
JP (1) JP2002504518A (de)
AT (1) ATE265224T1 (de)
AU (1) AU2610799A (de)
DE (1) DE69916811T2 (de)
WO (1) WO1999043341A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
WO2001051071A2 (en) * 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
ES2253353T3 (es) 2000-03-08 2006-06-01 Novo Nordisk A/S Reduccion del colesterol serico.
AU6479101A (en) 2000-06-16 2002-01-02 Lilly Co Eli Glucagon-like peptide-1 analogs
EP1346722B1 (de) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
US7271149B2 (en) * 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US7101843B2 (en) 2001-08-23 2006-09-05 Eli Lilly And Company Glucagon-like peptide-1 analogs
BRPI0408978B8 (pt) 2003-04-08 2021-07-27 Novo Nordisk As processos para regenerar uma fase estacionária cromatográfica
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
EP1694278A4 (de) 2003-12-16 2009-08-12 Ipsen Pharma Glp-1 pharmazeutische zusammensetzungen
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
EP2330126B1 (de) 2004-10-07 2015-12-23 Novo Nordisk A/S Exendin-4-Zusammensetzungen mit verlängerter Halbwertszeit
EP2494983B1 (de) 2004-11-12 2019-04-24 Novo Nordisk A/S Stabile formulierung von glp-1
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN101128214A (zh) 2005-03-18 2008-02-20 诺和诺德公司 长效glp-1化合物
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
WO2011089255A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
EP2555791B1 (de) 2010-04-09 2017-11-01 Sinai Health System Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
KR20130093470A (ko) 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
EP3326620B1 (de) 2010-12-16 2020-03-04 Novo Nordisk A/S Feste zusammensetzungen mit einem glp-1-agonisten und einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure
EP4324475A1 (de) 2012-03-22 2024-02-21 Novo Nordisk A/S Zusammensetzungen von glp-1-peptiden und herstellung davon
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
EP2873422A4 (de) 2012-07-10 2015-12-30 Takeda Pharmaceutical Pharmazeutische zubereitung zur injektion
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
EP2981282B1 (de) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Wachstumshormonverbindungsformulierung
EP3006045B3 (de) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmazeutische Formulierungen zur oralen Verabreichung von Peptid- oder Proteinarzneimitteln
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TW202024134A (zh) 2018-12-21 2020-07-01 大陸商江蘇恆瑞醫藥股份有限公司 雙特異性蛋白
CN115135305A (zh) 2020-02-18 2022-09-30 诺和诺德股份有限公司 药物制剂
EP4142695A1 (de) 2020-04-29 2023-03-08 Novo Nordisk A/S Feste zusammensetzungen mit einem glp-1-agonisten und histidin
US20240041983A1 (en) 2020-09-07 2024-02-08 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
CN115925995A (zh) 2020-09-30 2023-04-07 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
CN116730902B (zh) * 2023-08-07 2023-11-21 杭州湃肽生化科技有限公司 一种合成利拉鲁肽的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3750402T3 (de) * 1986-05-05 1997-04-10 Gen Hospital Corp Insulinotropes hormon.
DE68929217T2 (de) * 1989-03-20 2000-11-30 Gen Hospital Corp Insulinotropes hormon
DE69129226T2 (de) * 1990-01-24 1998-07-30 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
DK0944648T3 (da) * 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater

Also Published As

Publication number Publication date
DE69916811T2 (de) 2005-04-14
EP1061946A1 (de) 2000-12-27
JP2002504518A (ja) 2002-02-12
ATE265224T1 (de) 2004-05-15
EP1061946B1 (de) 2004-04-28
AU2610799A (en) 1999-09-15
WO1999043341A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
DE69916811D1 (de) Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
WO1999043361A8 (en) Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999006545A3 (en) Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
EE9500034A (et) Oksalüülaminobensofuraan- ja -bensotienüülderivaadid, nende valmistamismeetod ja kasutamine
CA2352625A1 (en) Cleavable solid dosage forms and method for the production thereof
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
HUP9900936A1 (hu) Izocianátalapú készítmények, bevonatként történő alkalmazásuk és az így előállított bevonatok
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
HK1058934A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
DE69725825D1 (de) 5-HT1F-Agonisten
MY127953A (en) Gabapentin-containing solid compositions and process for preparing the same
ES2068803T1 (es) Aditivo para evitar la corrosion de metales en materiales de construccion, procedimiento para la fabricacion de materiales de construccion utilizando el inhibidor de corrosion y materiales de construccion que contienen el inhibidor de corrosion.
ATE413388T1 (de) Muskarin antagonisten
EE9800022A (et) Karbapeneemühend, selle stabiliseerimismeetod ja stabiliseeritud vorm ning farmatseutiline kompositsioon
ATE229518T1 (de) Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
ES2178209T3 (es) Procedimiento para preparar una composicion de asfalto.
DE69808475T2 (de) Aminosäurederivate zur behandlung von schlaganfall
IS2611B (is) Fullkomið fóður fyrir fiskseiði og aðferð til að búa það til
ATE231141T1 (de) (-)-enantiomere von cis-3,4-chromanderivaten zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
HUT39601A (en) Process for producing synergistic contraceptive compositions
EA199900479A1 (ru) Стабилизированные фармацевтические композиции на основе хинупристина и дальфопристина и способ получения
ATE229519T1 (de) Neue cis-3,4-chromanderivate zur vorbeugung oder behandlung von oestrogenbezogenen krankheiten oder syndromen
BR0112123A (pt) Composto

Legal Events

Date Code Title Description
8364 No opposition during term of opposition